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A B S T R A C T
Purpose: Topiramate is an effective anti-epileptic drug and can be associated with increased risk for
urolithiasis because of its effects on acid–base proﬁle. Evidences that supported an association of
topiramate and urolithiasis were limited to case reports or series. We investigated the association of
topiramate and urolithiasis in a nationwide population-based cohort study.
Methods: We analyzed 1377 patients receiving topiramate and 1377 age- and gender-matched control
patients (not receiving topiramate) between 1997 and 2008. The risk of urolithiasis was analyzed using
Kaplan–Meier analysis, followed by Cox proportional hazard regression.
Results: Of the 2754 patients, 79 (2.9%) patients developed urolithiasis in two (interquartile range:
1.2–4.2) years. The proportion of patients who developed urolithiasis in the patients receiving
topiramate was not different from that of the control patients (p = 0.138, x2 test). The urolithiasis free
survival was not different between the patients receiving topiramate and the control patients (p = 0.168)
in Cox proportional hazard regression. The duration and total dosage of topiramate were not associated
with risk of urolithiasis in patients receiving topiramate (p = 0.482 and p = 0.751).
Conclusion: Topiramate may not increase the risk of urolithiasis. The duration and the total dosage of
topiramate were not associated with urolithiasis risks.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Topiramate is an effective antiepileptic drug for seizure [1] and
migraine [2]. As other antiepileptic drug, topiramate posed the
adverse effect of central nervous system, such as drowsiness and
mental suppression. However, topiramate has two unusual non-
neurological side effects: urolithiasis [3–5] and body weight loss
[6,7]. Topiramate can cause metabolic acidosis through the
inhibition of carbonic anhydrase. The risk of urolithiasis may be
increased through the increased urinary pH, urinary bicarbonate
excretion in patients receiving topiramate [8].
Studies for urolithiasis in patients receiving topiramate were
limited to case reports, case series [3–5,9], and biochemical* Corresponding author at: Division of Nephrology and Kidney Institute,
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Road, North District, Taichung 40447, Taiwan. Tel.: +886 4 22052121x3483;
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1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights recharacteristics that favor stone formation [8,10,11]. So far, there
was no observational cohort study that compares the risk of
urolithiasis in patients receiving and not receiving topiramate. The
aim of the study was to investigate topiramate associated
urolithiasis using a nationwide population-based cohort.
2. Methods
2.1. Database
We extracted data from a sampling longitudinal subset of
National Health Insurance Research Dataset (NHIRD). The NHIRD
contains all claim data that covered over 99% of the total
population in Taiwan (approximately 23.72 million individuals).
The sampling longitudinal subset, published by National Health
Research Institute of Taiwan, contained the ambulatory service
and hospitalization records of 1,000,000 individuals. The subset
was randomly sampled from the NHIRD and was divided into 25
equal groups. There is no signiﬁcant difference in distribution ofserved.
Fig. 1. Urolithiasis-free survival of patients receiving topiramate and control
patients.
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NHIRD. All the personal identiﬁers were encrypted before
published. The conﬁdentiality was assured by the data regulations
of the Bureau of National Health Insurance.
2.2. Study sample
We analyzed all patients who took topiramate (ATC code
N03AX11) between January 1, 1997 and December 31, 2008 in the
NHIRD subset (n = 1880). Patients treated with topiramate less
than 30 days (n = 503) were excluded. The analyzed cohort
consisted 1377 patients receiving topiramate and 1377 control
patients. Most of the patients took topiramate for seizure or
migraine. The control patients were selected from patients who
were not receiving topiramate and were matched for their age,
gender, and year of enrollment.
2.3. Study design
The earliest date of topiramate prescribed was recorded as an
index date. In control patients, the index date was deﬁned as the
date of ﬁrst visit. Each patient was individually tracked from the
index date to the last ambulatory service visit. Urolithiasis events
were deﬁned using ICD-9-CM code 592.x for kidney or ureter
stone, 594.x for bladder and urethra stone, and 602.0 for prostate
stone. A history of urolithiasis was deﬁned as patients with
urolithiasis diagnosed before the index date. The end of observa-
tion was deﬁned as the date of urolithiasis diagnosed or the last
ambulatory service visit if no urolithiasis identiﬁed. The time from
index date to the end of observation was recorded for urolithiasis
free survival analysis. Gouty arthritis was deﬁned as ICD-9-CM
code 274.x. In patients who took topiramate, duration and total
dosage of topiramate were calculated.
2.4. Statistical analysis
Data are reported as mean  SD for normally distributed
variables, median and interquartile range for not normally distributed
continuous variables, or percent frequency for categorical variables.
Pearson x2 tests were used to determine the differences in categorical
variables. The risk of urolithiasis was analyzed using Kaplan–Meier
analysis with log-rank test. Variables that may be associated with
urolithiasis were analyzed using Cox proportional hazard regression
and hazard ratios (HRs) and 95% conﬁdence interval (CI) were
calculated. A p value lower than 0.05 was considered statistically
signiﬁcant. All statistical analyses were performed using SAS
statistical package, version 9.1 (SAS, Inc., NC, USA).
3. Results
Patients’ age and the proportion of male gender were not
different in patients receiving topiramate and the control patients
(Table 1). Of the patients receiving topiramate, 46 (3.3%) patientsTable 1
Demographics of patients who took topiramate and patients who did not took
topiramate (control) in 1997–2008.
Variable Topiramate
n = 1377
Control
n = 1377
p
Age (year) 38.2 20.5 38.3 20.5 1.000
Follow-up (year) 2.3 1.3–4.3 2.8 2.1 0.200
Male 613 44.5 613 44.5 1.000
Urolithiasis 46 3.3 33 2.4 0.138
History of urolithiasis 67 4.9 84 6.1 0.158
Gouty arthritis 121 8.8 142 10.3 0.173
Data was expressed as mean  standard deviation (SD) or n percentage as appropriate.developed urolithiasis in 2.3 (1.3–4.3) years. The percentage of
patients who developed urolithiasis was not different to that (2.4%)
of the control patients (p = 0.138). The duration of follow-up, the
proportion of patients with a history of urolithiasis, and the
proportion of patients with gouty arthritis in patients who took
topiramate were not different from that of control patients. The
urolithiasis free survival (Fig. 1) was not different in patients
receiving topiramate and the control patients (p = 0.166, log-rank
test). In multivariable Cox regression for possible risk factors of
urolithiasis (Table 2), the use of topiramate was not associated
with a higher risk of urolithiasis (p = 0.13). A history of urolithiasis
was the most important risk factors for the development of
urolithiasis with a HR of 17.78 (95% CI: 11.12–28.43, p < 0.01).
Patients’ age was signiﬁcantly associated with the risk of
urolithiasis and the HR was 1.13 (95% CI: 1.00–1.28, p = 0.04)
for every 10 additional years. Male gender and a history of gout
arthritis were not associated with the risk of urolithiasis.
In patients receiving topiramate (Table 3), patients with
urolithiasis were older (p = 0.009), more likely to be male
(p = 0.049), and more likely to have a history of urolithiasis
(p < 0.001). The duration and the total dosage of topiramate were
not different in patients with and without urolithiasis. In patients
receiving topiramate, a history of urolithiasis was associated with
the risk of urolithiasis (Table 4) with an aHR of 10.45 (95% CI: 5.17–
21.22, p < 0.001). Male patients were associated with a higher risk
of urolithiasis (p = 0.049) with an aHR of 1.87 (95% CI: 1.00–3.49).
The duration of topiramate had no effect on the risk of urolithiasis
(p = 0.482) and the total dosage of topiramate was not associated
with increased risk for urolithiasis (p = 0.751).
4. Discussion
This is the ﬁrst observational cohort study in investigating the
risk of urolithiasis in patients receiving topiramate. We found thatTable 2
Multivariable Cox regression of possible risk for urolithiasis in patients receiving
and not receiving topiramate (n = 2754).
Variable HR 95% CI p
Topiramate 1.64 0.91–2.58 0.13
History of urolithiasis 17.78 11.12–28.43 <0.01
Age (every 10 additional years) 1.13 1.00–1.28 0.04
Male 1.54 0.97–2.44 0.07
Gouty arthritis 1.29 0.97–2.44 0.41
Table 3
Demographics and clinical features of patients receiving topiramate between 1997 and 2008 (n = 1377).
Variable Urolithiasis (+)
n = 46
Urolithiasis ()
n = 1331
p
Age (year) 46.0 15.1 38.0 20.6 0.009
Male n% 27 58.7 586 44.0 0.049
History of urolithiasis 15 32.6 52 3.9 <0.001
Gouty arthritis 7 15.2 114 8.6 0.117
Duration of topiramate (month) 2.9 1.4–12.1 4.7 1.7–16.8 0.182
Total topiramate amount (100 mg) 95.0 22.5–371.0 91.0 28.0–423.8 0.133
Data is expressed as mean  SD, or median and interquartile range.
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This conclusion was supported by four ﬁndings. First, the
proportion of patients who developed urolithiasis was similar in
patients receiving topiramate and the control patients (Table 1).
Second, the urolithiasis free survival curve was not different in
patients receiving topiramate and control patients (Fig. 1). Third,
the use of topiramate was not associated with higher urolithiasis in
multivariable Cox regression (Table 2). Fourth, the duration and
total dosage of topiramate were not associated with increased risk
of urolithiasis (Table 3). The large patient number was one of the
major strength of this study.
The development of urolithiasis can be summarized in three
pathways [12]: overgrowth on interstitial apatite plaque such as
idiopathic calcium oxalate stone, crystal deposits in renal tubules,
and free solution crystallization such as cystinuria or hyperox-
aluria. Overgrowth on interstitial apatite plaque may be the
pathway responsible for the development of urolithiasis in
patients receiving topiramate [5,10,12–16]. In the pathway, the
increased urinary oxalate [8,11,14] may deposit on the plaque and
increase the sizes of the stones. Larger stones were easier to be
identiﬁed in X-ray or ultrasound in clinical settings. However,
information regarding the component of the stone was not
available and we were not able to investigate this hypothesis.
Among the variables analyzed, a history of urolithiasis was the
most powerful predictor of urolithiasis (Tables 2 and 4) and was
associated with a ten-fold increase of risk of urolithiasis. In a
subgroup analysis of patients with a history of urolithiasis, all
variables including age, sex, and gout were not associated with the
risk of urolithiasis. In 151 patients with a history of urolithiasis,
topiramate was not associated with increased risk of urolithiasis
(p = 0.355). The analysis of patients with a history of urolithiasis
may provide better adjustments for the confounders that were not
available in the NHRID such as family history [17], diet [18,19] and
anatomical abnormalities associated with stone formation [20].
Since information of treatments and the results of treatment (if the
stone was removed) of urolithiasis were not available in the
NHRID, it is not possible to identify if these urolithiasis were
recurrent stones or residual stone after incomplete treatment.
There were some potential limitations of the study. First,
performance bias cannot be completely avoided as clinicians mayTable 4
Hazard ratio (HR) of variables for urolithiasis in patients receiving topiramate in
multivariable Cox regression.
Variable aHR 95% CI p
Topiramate duration
(every 1 month longer)
1.00 0.99–1.00 0.482
Total dosage of topiramate
(every 100 mg more)
1.00 1.00–1.00 0.751
History of urolithiasis 10.45 5.17–21.11 <0.001
Male 1.87 1.00–3.49 0.049
Age 1.01 0.999–1.02 0.499
Gouty arthritis 1.15 0.47–2.83 0.765be aware of the possible adverse effect of topiramate and,
therefore, perform more tests. This may increase the chance of
urolithiasis found in patients receiving topiramate. In contrast,
urolithiasis in control patients may be left unnoticed until it was
found accidently or diagnosed when the patents developed certain
symptoms associated with urolithiasis. Second, urolithiasis was
identiﬁed using ICD-9-CM code and this may under-estimate the
prevalence of urolithiasis [21]. The under-estimation of urolithia-
sis may have a limited effect on the result because the under-
estimated incidence of urolithiasis affected both patients receiving
topiramate and control patients. Third, the diagnosis of urolithiasis
may be not made in uniform measurements because urolithiasis
was deﬁned using ICD-9-CM code. A diagnosis of urolithiasis can
be made based on the ﬁndings of computer tomography, X-ray,
ultrasound, or clinical manifestations such as ﬂank pain, gross
hematuria, and no signs of urinary tract infection. Despite of the
limitations, this study was the only cohort study for urolithiasis in
patients taking topiramate. Patients with urolithiasis were
excluded in most of the randomized controlled trials [2,22,23]
and the development of urolithiasis was not recorded in these
randomized controlled trials.
In conclusion, topiramate may not be associated with increased
risk for urolithiasis in an observational nationwide cohort study.
The duration of topiramate and the total dosage of topiramate had
no effect on stone formation in patients treated with topiramate.
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